



Gynecologic Oncology University Health Network/ Sinai Health Systems

Annual Research Report 2020

Table of Contents	
Goals and Vision Statement	3
Surgeon-Scientists	4
Research Team Members	5
Highlights	6
Funding Awards	7
Studies and Recruitment	8-10
Presentations and Publications	11-22

Gynecologic Oncology Research at Princess Margaret



VISION AND GOALS

- ❖ To expand and promote **clinical, translational and educational research** by integration in the clinical care setting.
- ❖ To become Canada's **leader** in Gynecologic Oncology, **improving outcomes** for all women with gynecologic cancer through excellence in patient care, research and education.

Our integrated approach includes:



ACTIVE SCREENING

Pre-screening gynecologic oncology clinics to identify patients eligible for our studies.



BIOBANKING

Collecting and banking blood samples from ovarian cancer patients and coordinating tissue collection for research.



COLLABORATION

Building relationships across disciplines for novel and innovative translational research.

Meet the Surgeon-Scientists



Dr. Marcus Bernardini

Dr. Bernardini is the Division Head of Gynecologic Oncology at the University Health Network. His research interests include: understanding the role of precursor lesions in high grade serous ovarian cancer, as well as cytoreductive surgery for later stage disease. He co-leads the ovarian cytoreductive program as well as CANSTIC, a Pan-Canadian study looking at treatment and outcomes of ovarian pre-cursor lesions. He is also lead investigator of the Early Stage Cohort of CANSTAMP.




Dr. Sarah Ferguson

Dr. Ferguson is Director of Research for the Division of Gynecologic Oncology. Her research interests are improving surgical techniques and patient outcomes, survivorship and supportive care as well as hereditary cancer syndromes in Gynecology, in particular Lynch Syndrome. She is the lead investigator for the SENTOR trial and for the Advanced Stage Cohort of CANSTAMP.




Dr. Stephane Laframboise

Dr. Laframboise is co-director of the Gynecology Oncology Fellowship Program at Princess Margaret. Her research interests are in vulvar cancer and Quality Improvement. She currently co-leads projects investigating vulvar cancer patient outcomes as well as the MIGOS initiative, a minimally invasive surgery/same day discharge quality improvement pathway.



Dr. Taymaa May

Dr. Taymaa May is the Surgical Oncology Lead for Toronto Central South. Dr. May is the medical director of the UHN ovarian cancer serum biobank and a member of the international Ovarian Cancer Association Consortium. Dr. May's translational research interests are in the field of serous ovarian malignancies. Dr. May is the principal investigator for the international NRG-GY019 study at Princess Margaret.




Dr. Liat Hogen

Dr. Hogen joined the division in 2017. Her research interests include predictive models for successful debulking in advanced ovarian cancer, and clinical aspects of rare subtypes of ovarian cancer. She is working on developing an integrated model for improved surgical outcome in ovarian cancer, as well as clinical and genomic studies in clear cell and endometrioid ovarian cancer.



Dr. Genevieve Bouchard-Fortier

Dr. Bouchard-Fortier joined the division in 2016. Her research is focused on improving the quality of care of gynecologic oncology patients as well as developing quality metrics to measure outcomes. Currently she leads a perioperative care program for minimally invasive gynecologic oncology surgical patients (MIGOS) to shorten length of stay, reduce opioid use, improve patient experience and reduce costs.



Dr. Paulina Cybulska

Dr. Cybulska joined the division in 2019. Her research interests are investigation of the tumour immune micro-environment in high grade serous ovarian cancer, geriatric oncology and granulosa cell tumors. She is currently collaborating with Dr. Laurie Ailles on a translational project examining the role of cancer-associated fibroblasts in mediation of chemo-resistance.

Meet the



Emily Van de Laar

Emily has been with the Gynecology Oncology team for 6 years. She has an MSc in Reproductive Biology from the University of Guelph and worked in basic research before joining the Gynecology Oncology team in 2014. She was genetic navigator for the Lynch Syndrome (LS2) study which successfully recruited and screened more than 900 participants at three cancer centres for Lynch Syndrome and connected more than 200 eligible patients with genetic counselling and testing. She works on study planning, logistics, budgets and data management. Her specific areas of research interest include: knowledge translation from the basic research lab into clinical practice, the role of genomics in modern cancer care, and data management- from database development to best practices for data security in a technologically advancing healthcare system.



Aysha Zia

Aysa has been with the Gynecology Oncology group for 5 years. She is on the forefront of clinical recruitment and interaction with patients. Her academic interests are Endometrial and Cervical cancer and Lynch Syndrome Studies, for which she's been the lead coordinator of SENTOR, SHAPE, LACC, Lynch Clinical and Cervical Sexual Health to name a few. She is currently involved in Qualitative projects like MIGOS and VIVIFY Health App to help improve the surgical quality and patient care experience at the UHN! Along with coordinating, she is also involved in REB documentations and data analysis/extraction for various studies.



Gabrielle Ene,

Gabby has been with the Gynecologic Oncology team for 5 years, focusing a majority of her work on hereditary ovarian cancer, and early endometrial cancer in young women desiring fertility preservation. She provides support with project logistics and development, ethics considerations, and grant development and submissions. As of January 2020, she took on the role as GYN Biobank Manager. She has been invited to represent the Division of Surgical Oncology-Gynecology on the CCRU QCC (Quarterly CAPCR Connect) aimed at streamlining study start-up procedures. Furthermore, she has been involved in the successful development of a new clinical trial, B-FIERCE, awarded the CCSRI Innovation Grant 2020, and Can-STIC, a national-based collaboration with the Society of Gynecologic Oncology of Canada.

HIGHLIGHTS 2020

1

Publications

31 total
12 last author
2 first author
17 co-author

2

Grant Funding


\$1,075,578 awarded

3

Patient Participation

5 actively recruiting studies
1 Quality Improvement initiative
1 Gynecology biospecimen bank

New Funding Awarded by Year



With the emergence of COVID-19 in 2020, on site research activity was reduced to prioritize the health and safety of patients and staff. Despite a challenging year, our research team, fellows and clinician investigators in Gynecology Oncology at Princess Margaret remained productive. When we were in clinic, we recruited patients to our 5 active studies and to our Gynecology Oncology biospecimen banking program. We had many posters to present and invitations to speak at international Gynecology Oncology conferences, including three plenary sessions. While COVID meant most conferences were moved to a digital format, we were extremely proud of the opportunity to showcase our hard work to the academic community.

Funding Awards

Ferguson SE. Innovation Grant, Canadian Cancer Society Research Institute. **\$190,116 CAD** (2020-2023) Bariatric Surgery for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (B-FiERCE): A Feasibility Study.

Ferguson SE. Uterine Carcinosarcoma and Other Aggressive Uterine Cancer Research Grant, Canadian Cancer Society Research Institute. **\$179,440 CAD** (2020-2022) Molecular Predictors of Response of Maintenance Poly (ADP-ribose) Polymerase Inhibition (PARPi) in Serous or p53 Abnormal Endometrial Cancer After Chemotherapy: Randomized Phase II Trial.

Ferguson SE. Operating Grant: Women's Health Clinical Mentorship Grant, Canadian Institutes of Health Research. **\$47,621 CAD** (2020-2021). Acceptability of Bariatric Surgery in Young Women with Cancer: A Qualitative Study.

Bernardini MQ. GTx Innovation competition, University Health Network Department of Surgical Oncology. **\$30,000 CAD** (2020-2021) Nanoparticle Intra-Operative Lymph Node Evaluation using Porphysomes in Endometrial Cancer Surgery – A Pilot Study.

Cybulska P. Violet River Research Award in Gynaecology, Mount Sinai Hospital Department of Obstetrics and Gynaecology. **\$30,000 CAD** (2020-2021). Defining the Role of Cancer Associated Fibroblasts in Sculpting the Tumor Immune Microenvironment in High-Grade Serous Ovarian Carcinoma.

Ferguson SE. Violet River Research Award in Gynaecology, Mount Sinai Hospital Department of Obstetrics and Gynaecology. **\$30,000 CAD** (2020-2021). Personalized medicine in endometrial cancer: using a one-stop molecular panel to inform treatment decisions and improve outcomes.

Ferguson SE. Knox Ritchie Award, Mount Sinai Hospital Department of Obstetrics and Gynaecology. **\$10,000 CAD** (2020-2021) Identifying Women with Morbid Obesity from Health Administrative Data: A Validation Study of Surgical Billing Codes.


May T. Intuitive Foundation Research Grant, Intuitive Foundation. **\$20,000 USD** (2020-2021). Long-term surgical and oncologic outcomes after robotic and vaginal radical trachelectomy in women with early stage cervical cancer: A Canadian multicenter experience.

Hogen L. Chair's Summer Research Student Award, University of Toronto Department of Obstetrics and Gynecology. **\$3,500 CAD** (2020). Endometrioid ovarian cancer: clinical features and prognosis of early stage.

Kislinger T. Project Grant, Canadian Institutes of Health Research. **\$504,901 CAD** (2020-2024). The Ovarian Cancer Glycoproteome: Biomarker Discovery and Therapeutic Targets. (Co-investigator: **Bernardini MQ**)

Jacobson M. Violet River Research Award in Gynaecology, Mount Sinai Hospital Department of Obstetrics and Gynaecology. **\$30,000 CAD** (2020-2021). Persistence of Fimbrial Tissue on the Ovarian Surface Following a Two-Step Risk-Reducing Bilateral Salpingo-Oophorectomy in BRCA 1/2 Mutation Carriers. (Co-investigator: **Bernardini MQ**)

Studies and Recruitment 2020



Molecular Profiling of Tumour Heterogeneity in High Grade Serous Ovarian Cancer

- Recruitment began in 2020

OCHP is a prospective study to collect and assess fresh ovarian tumour tissue by single cell RNA-Seq to characterize the tumour microenvironment in primary ovarian tumours and their metastatic deposits. Recruitment began in 2020 with 8 consented patients. Only a handful of these cases produced sufficient, high quality tissue for the study, but we hope to complete 10 successful case analyses by the end of 2021.

Acceptability of bariatric surgery in young women with endometrial cancer and atypical hyperplasia: a qualitative study

- Recruitment began in 2020

The B-Fierce feasibility pilot study is an exciting precursor to a planned prospective study to investigate the use of bariatric surgery for weight management in gynecologic cancer patients with low grade (grade 1) endometrioid endometrial cancer who wish to retain fertility. The pilot study is an interview with this patient population asking them questions about weight, fertility, endometrial cancer and bariatric surgery. Based on the acceptability of this approach to patients, the B-Fierce study will roll out to actually offer bariatric surgery to eligible patients. In 2020, 12 patients were interviewed, analysis will be completed in 2021.

PI: Dr. Liat Hogen

- PI: Dr. Marcus Bernardini

- PI: Dr. Sarah Ferguson

A bar chart with two categories on the x-axis: '# of surgical patients screened' and '# of surgical patients eligible'. The y-axis represents the count, ranging from 0 to 600 in increments of 100. The first bar, for 'screened' patients, is purple and reaches a value of approximately 550. The second bar, for 'eligible' patients, is also purple and reaches a value of 100.

Category	Count
# of surgical patients screened	550
# of surgical patients eligible	100

- Recruitment completed in 2020

Post-operative Opioid Stewardship in Gynecologic Oncology: Prescription Patterns of Physicians, and Use by Patients

- Recruitment completed in 2020

10

Publications and Presentations

International

International Gynecologic Cancer Society (IGCS) Annual Global Meeting September 10-13, 2020

ORAL PLENARY PRESENTATIONS

Cusimano MC, Vicus D, Pulman K, Bernardini MQ, Laframboise S, May T, Bouchard-Fortier G, Hogen LF, Gien LT, Covens AL, Kupets R, Clarke BA, Cesari M, Rouzbahman M, Turashvili G, Maganti M, Zia A, Ene G, **Ferguson SE**. Sentinel lymph node biopsy versus lymphadenectomy for intermediate and high grade endometrial cancer staging (SENTOR Trial): A prospective multicenter cohort study. Oral Plenary presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Kim RS, Tone AA, Pollett A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Lytwyn A, Maganti M, Oldfield LE, Pugh TJ, Gallinger S, Bernardini MQ, Oza AM, Dube V, Lerner-Ellis J, Van de Laar E, Vicus D, **Ferguson SE**. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Oral Plenary presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

ORAL FEATURED POSTERS

Kim RS, Maganti M, Bernardini MQ, Laframboise S, Ferguson SE, **May T**. Long-term survival outcomes of intravenous vs intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. Oral Featured Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Kim SR, Oldfield LE, Tone AA, Pollett A, Van de Laar E, Pederson S, Wellum J, Clarke BA, Pugh TJ, **Ferguson SE**. Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel. Oral Featured Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Hogen L, Laframboise S, May T, Ding A, **Bernardini MQ**. Integrated model of patient factors, resectability score and surgical complexity index to predict surgical outcome in debulking surgery for advanced ovarian cancer. Oral Featured Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

POSTERS

Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod S, **May T**. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on ten-year survival from advanced ovarian cancer. Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Kim SR, Tone AA, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield LE, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van

de Laar E, Vicus D, Pugh TJ, Pollett A, **Ferguson SE**. Performance characteristics of screening strategies to identify Lynch syndrome in women with non-serous and non-mucinous ovarian cancer. Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Kim RS, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod SA, **May T**. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on ten-year survival from advanced ovarian cancer. Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Kim RS, Tone AA, Pollett A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Lytwyn A, Maganti M, Oldfield LE, Pugh TJ, Gallinger S, Bernardini MQ, Oza AM, Dube V, Lerner-Ellis J, Van de Laar E, Vicus D, **Ferguson SE**. Discordant mismatch repair protein expression in synchronous endometrial and ovarian cancers. Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Nica A, Kim SR, Gien L, Covens A, Bernardini M, Bouchard-Fortier G, Kupets R, Hogen L, Laframboise S, May T, Vicus D, **Ferguson SE**. Survival after minimally invasive surgery in early cervical cancer: Is the uterine manipulator to blame? Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Nica A, Sutradhar R, Covens A, Kupets R, Vicus D, Li Q, **Ferguson SE**, Gien L. Pre-operative wait times in high risk endometrial cancer: do surgical delays impact patient survival? Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Nica A, Sutradhar R, Kupets R, Covens A, Vicus D, Li Q, **Ferguson SE**. Outcomes after the regionalization of care for high risk endometrial cancers: a population-based study. Poster presented at: Annual Global Meeting of the International Gynecologic Cancer Society. 2020 Sep 10-13. (moved to virtual format due to COVID-19)

Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer
Mar 28-31, 2020

SCIENTIFIC PLENARY

Cusimano MC, Vicus D, Pulman K, Bernardini MQ, Laframboise S, May T, Bouchard-Fortier G, Hogen LF, Gien LT, Covens AL, Kupets R, Clarke BA, Cesari M, Rouzbahman M, Turashvili G, Maganti M, Zia A, Ene GEV, **Ferguson SE**. Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study. Scientific Plenary presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

FEATURED POSTERS

Cusimano MC, Classen CC, Koval J, Barbera L, Brotto LA, Chivers ML, Carter J, Ferguson SE. Association of treatment modality with sexual dysfunction in gynecologic cancer survivors: A secondary analysis of the gyne-GALS randomized controlled trial. Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Kim RS, Pollett A, Tone A, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Litwin A, Maganti M, Oldfield L, Pugh T, Van de Laar E, Vicus D, **Ferguson SE**. Performance characteristics of screening strategies to identify Lynch syndrome in women with non-serous and non-mucinous ovarian cancer. Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Swift BE, Philp L, Atenafu EG, Malkani AN, Gien LT, **Bernardini MQ**. Lymphadenectomy for high-risk endometrial cancer: Does it impact lymph node recurrence? Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Tone A, Van de Laar E, Holter S, Aronson M, Eirikksson L, Vicus D, Lerner-Ellis J, Pollett A, Cesari M, Hart T, Lytwyn A, Clarke B, **Ferguson SE**. Use of a genetic navigator to maximize Lynch syndrome detection in women with endometrial and non-serous/mucinous ovarian cancer. Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Wohlmuth C, Tone AA, Daghrach A, Stickle N, Virtanen C, Brown TJ, **May T**. Risk stratification using hotspot genotyping in low-grade serous ovarian cancer. Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

POSTERS

Bouchard-Fortier G, Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, May T, Bouchard-Fortier A, **Ferguson SE**. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Cusimano MC, Sajewycz K, Nelson M, Jivraj N, Bowering S, Lee YC, Lheureux S, **Ferguson SE**. Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Dong S, Hogen L, Romanovsky L, Alibhai S, Bernardini MQ, May T, Laframboise S, Bouchard-Fortier G, Ferguson SE, Li X, Cybulski P. Perioperative outcomes and survival in elderly women with ovarian cancer. Featured poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Kim RS, Pollett A, Tone A, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Lytwyn A, Lu L, Oldfield L, Pugh T, Van de Laar E, Vicus D, **Ferguson SE**. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Kim RS, Pollett A, Tone A, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Lytwyn A, Maganti M, Oldfield L, Pugh T, Van de Laar E, Vicus D, **Ferguson SE**. Assessment of strategies to identify Lynch syndrome in women with synchronous endometrial and ovarian cancers. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Nica A, Kim SR, Gien L, Covens A, Bernardini M, Bouchard-Fortier G, Kupets R, Hogen L, Laframboise S, May T, Vicus D, **Ferguson SE**. Survival after minimally invasive surgery in early cervical cancer: Is the uterine manipulator to blame? Poster presented at: Society of Gynecologic

Nica A, Lee JJY, Look Hong N, **May T**. Cost-effectiveness of maintenance hormonal therapy in patients with advanced low-grade serous ovarian cancer. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

Wohlmuth C, Wohlmuth-Wieser I, May T, Vicus D, Gien LT, **Laframboise S**. Malignant melanoma of the vulva and vagina: A study of 1863 cases. Poster presented at: Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. 2020 Mar 28-31. (moved to virtual format due to COVID-19)

The Farr Nezhat Surgical Innovation Session- Invited Speaker

**American Society of Clinical Oncology (ASCO) Annual Meeting
May 29-31, 2020**

Kim SR, Oldfield LE, Tone AA, Pollett A, Van de Laar E, Pederson S, Wellum J, Clarke BA, Pugh TJ, **Ferguson SE**. Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting. 2020 May 29-31. (moved to virtual format due to COVID-19)

American College of Surgeons Clinical Congress

14

American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting-Digital Edition

Oldfield L, Kim RS, Pedersen S, Wellum J, Pollett A, Tone A, Cesari M, Clarke BA, Eiriksson L, Hart T, Holter S, Lytwyn A, Maganti M, Van de Laar E, Vicus D, **Ferguson SE**, Pugh TJ. Assessment of mutational profile in Lynch-Syndrome associated ovarian cancers. American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting-Digital Edition. 2020 Mar 17-21. (moved to virtual format due to COVID-19)

24th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer

Kim RS, Tone AA, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner- Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, **Ferguson SE**. Performance characteristics of screening strategies to identify Lynch syndrome in women with non-serous and non-mucinous ovarian cancer. Presented at: 24th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC). 2020 Nov 14. (moved to virtual format due to COVID-19)

American Society for Radiation Oncology (ASTRO) 62nd Annual Meeting

Croke J, Conway J, Conroy J, **Ferguson SE**, Zia A, Liu Z, Weiss J, Rink A. Patient reported outcomes, physician-reported toxicity and dosimetry in cervix cancer patients treated with chemoradiation and MR-guided brachytherapy. Presented at: American Society for Radiation Oncology (ASTRO) 62nd Annual Meeting. (moved to virtual format due to COVID-19); 2020 Oct 24-28.

The European Society for Radiotherapy and Oncology (ESTRO) World Congress of Brachytherapy

Croke J, Conway J, Conroy J, **Ferguson SE**, Zia A, Liu Z, Weiss J, Rink A. Patient reported outcomes, physician-reported toxicity and dosimetry in cervix cancer patients treated with chemoradiation and MR-guided brachytherapy. Planned presentation at: The European Society for Radiotherapy and Oncology (ESTRO) World Congress of Brachytherapy. (moved to virtual format due to COVID-19); 2020 Jul 31 (Conference cancelled due to COVID-19).

Digestive Disease Week

Tinmouth J, Zwaal C, Gryfe JC, Carroll B, McCurdy B, Baxter N, **Ferguson SE**. What is the evidence for cancer screening and cancer risk reduction strategies in persons at risk for or affected with Lynch Syndrome? Planned presentation at: Digestive Disease Week. Chicago, IL; 2020 May 2-5. (Conference cancelled due to COVID-19)

National

The Society of Gynecologic Oncology Canada (GOC) Annual General Meeting October 14-17, 2020

Bouchard-Fortier G, Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, May T, Bouchard-Fortier A, **Ferguson SE**. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Awarded Best Oral Presentation at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, May T, Bouchard-Fortier G, **Ferguson SE**. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. Oral abstract presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Hogen L, Laframboise S, May T, Ding A, **Bernardini MQ**. Integrated model of patient factors, resectability score and surgical complexity index to predict surgical outcome in debulking surgery for advanced ovarian cancer. ePoster presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Kim SR, Maganti M, Bernardini MQ, Laframboise S, Ferguson SE, **May T**. The prolonged survival benefits of intravenous versus intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. ePoster (top 5) presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod S, **May T**. The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on ten-year survival from advanced ovarian cancer. ePoster (top 5) presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Marchocki Z, **May T**. High laparoscopic bilateral ovarian transposition to the upper abdomen prior to pelvic radiotherapy. Oral video presentation at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Nguyen J, Bernardini MQ, Ferguson SE, May T, Cybulska P, Hogen L, Laframboise S, **Bouchard-Fortier G**. Postoperative opioid stewardship in gynecologic oncology. Oral abstract presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Nguyen J, Vicus D, Bernardini MQ, **Hogen L**. Patients with ovarian clear cell carcinoma are at high risk of secondary malignancy. ePoster presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

Invited Speaker

May T. Advances in the field of ovarian cancer- Distillation of research abstract. Presented at: Virtual 40th Annual General Meeting of the Society of Gynecologic Oncology of Canada. 2020 Oct 14-17. (moved to virtual format due to COVID-19)

INVITED SPEAKER PRESENTATIONS

23rd Annual E. Earle Dilworth M.D. Resident Research Forum

Ferguson SE. Management of endometrial cancer – Evolution of personalized treatment. Presented at: 23rd Annual E. Earle Dilworth M.D. Resident Research Forum. LSU Health Shreveport, Department of Obstetrics and Gynecology. Shreveport, Louisiana, United States. 2020 Jun 5.

GOC Community of Practice Annual Digital Meeting

May T. Effectiveness of PARP-inhibitors in the management of advanced ovarian cancer in the first line setting. Presented at: Society of Gynecologic Oncology of Canada (SGOC) Community of Practice Annual Digital Meeting; 2020 Nov 20.

Ovarian Cancer Canada's National Virtual Symposium

May T. Living with ovarian cancer- Expert review and recommendations. Presented at: Ovarian Cancer Canada's National Virtual Symposium; 2020 Oct 24.

Local

University of Toronto Department of Obstetrics and Gynecology Annual Research Day May 8, 2020


Kim SR, Kotsopoulos J, Sun P, Bernardini MQ, Laframboise S, Ferguson SE, Rosen B, Narod S, **May T.** The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on ten-year survival from advanced ovarian cancer. Planned presentation at: University of Toronto Department of Obstetrics and Gynecology Annual Research Day; 2020 May 8. (Conference cancelled due to COVID-19).

Kim RS, Maganti M, Bernardini MQ, Laframboise S, Ferguson SE, **May T.** Long-term survival outcomes of intravenous vs intraperitoneal chemotherapy in the treatment of advanced ovarian cancer. Planned presentation at: University of Toronto Department of Obstetrics and Gynecology Annual Research Day; 2020 May 8. (Conference cancelled due to COVID-19).

Nguyen J, Bernardini MQ, Ferguson SE, May T, Cybulska P, Hogen L, Laframboise S, **Bouchard-Fortier G.** Postoperative opioid stewardship in gynecologic oncology. Planned presentation at: University of Toronto Department of Obstetrics and Gynecology Annual Research Day; 2020 May 8. (Conference cancelled due to COVID-19).

Nguyen J, Vicus D, Nofech-Mozes S, Gien LT, Bernardini MQ, **Hogen L.** Patients with ovarian clear cell carcinoma are at high risk of a second primary malignancy. Planned presentation at: University of Toronto Department of Obstetrics and Gynecology Annual Research Day; 2020 May 8. (Conference cancelled due to COVID-19).

Publications by Year



First or Last Author Publications

Nguyen JMV, Vicus D, Nofech-Mozes S, Gien LT, Bernardini MQ, Rouzbahman M, **Hogen L**. Risk of second malignancy in patients with ovarian clear cell carcinoma. *Int J Gynecol Cancer* [Internet]. 2020 Dec 18;31(4):545–52. Available from: <http://dx.doi.org/10.1136/ijgc-2020-001946>

Nica A, Kim SR, Gien LT, Covens A, Bernardini MQ, Bouchard-Fortier G, Kupets R, May T, Vicus D, Laframboise S, Hogen L, Cusimano MC, **Ferguson SE**. Survival after minimally invasive surgery in early cervical cancer: is the intrauterine manipulator to blame? *Int J Gynecol Cancer* [Internet]. 2020 Oct 9;30(12):1864–70. Available from: <http://dx.doi.org/10.1136/ijgc-2020-001816>

Govindarajan M, Wohlmuth C, Waas M, **Bernardini MQ**, Kislinger T. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. *J Hematol Oncol* [Internet]. 2020 Oct 9;13(1). Available from: <http://dx.doi.org/10.1186/s13045-020-00971-6>

Oldfield LE, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, **Ferguson SE**. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. *Int J Gynecol Cancer* [Internet]. 2020 Oct 20;30(12):1951–8. Available from: <http://dx.doi.org/10.1136/ijgc-2020-001927>

Nica A, Covens A, Parra-Herran C, **May T**. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer? *Gynecol Oncol* [Internet]. 2020 Sep;158(3):622–30. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.06.478>

Bouchard-Fortier G, Ghorani E, Short D, Aguiar X, Harvey R, Unsworth N, Kaur B, Sarwar N, Seckl MJ. Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse? *Gynecol* [Internet]. 2020 Sep;158(3):698–701. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.06.483>

Kim RS, Tone AA, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, **Ferguson SE**. Performance characteristics of screening strategies to identify Lynch Syndrome in women with ovarian cancer. *Cancer* [Internet]. 2020 Aug 18;126(22):4886–94. Available from: <http://dx.doi.org/10.1002/cncr.33144>

Nguyen JMV, Ferguson SE, Bernardini MQ, May T, Laframboise S, Hogen L, **Bouchard-Fortier G**. Preoperative neutrophil-to-lymphocyte ratio predicts 30-day postoperative morbidity and survival after primary surgery for ovarian cancer. *Int J Gynecol Cancer* [Internet]. 2020 Aug 11;30(9):1378–83. Available from: <http://dx.doi.org/10.1136/ijgc-2020-001378>

Marchocki Z, Rouzbahman M, Chawla T, **May T**. Management of low-grade serous ovarian neoplasm in the setting of fertility preservation. *Int J Gynecol Cancer* [Internet]. 2020 Aug 5;30(11):1834–9. Available from: <http://dx.doi.org/10.1136/ijgc-2020-001838>

Nguyen JMV, Hogen L, Laframboise S, Bouchard-Fortier G, Ferguson SE, Bernardini MQ, **May T**. The use of indocyanine green fluorescence angiography to assess anastomotic perfusion following bowel resection in surgery for gynecologic malignancies - A report of 100 consecutive anastomoses. *Gynecol Oncol* [Internet]. 2020 Aug;158(2):402–6. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.05.008>

Bouchard-Fortier G, Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, May T, Bouchard-Fortier A, **Ferguson SE**. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis. *Gynecol Oncol* [Internet]. 2020 Jul;158(1):218–28. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.03.034>

May T, Oza AM. Measurement tool of chemotherapy sensitivity in advanced ovarian cancer. *Clin Cancer Res* [Internet]. 2020 Jun 29;26(17):4432–4. Available from: <http://dx.doi.org/10.1158/1078-0432.CCR-20-1376>

Cybulska P, Jimenez-Sanchez A1, LaVigne Mager K1, Koplev S, Cast O, Laurent-Couturier D, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Papanestasiou AD, Sosa RE, Soslow RA, Walther T, Shen R, Chi DS, Park KJ, Hollmann T, Resi-Filho JS, Markowitz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, Sala E, Miller ML. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. *Nat Genet* [Internet]. 2020 Jun;52(6):582–93. Available from: <http://dx.doi.org/10.1038/s41588-020-0630-5>

Cusimano MC, Sajewycz K, Nelson M, Jivraj N, Lee YC, Bowering V, Oza A, Lheureux S, **Ferguson SE**. Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. *Gynecol Oncol* [Internet]. 2020 Jun;157(3):745–53. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.03.009>

Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, **May T**. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. *Eur J Cancer* [Internet]. 2020 Mar ;127 :76–95. Available from: <http://dx.doi.org/10.1016/j.ejca.2019.10.034>

Co-author Publications

Cusimano MC, Moineddin R, Chiu M, **Ferguson SE**, Aktar S, Liu N, Baxter NN. Practice variation in bilateral salpingo-oophorectomy at benign abdominal hysterectomy: A population-based study. *Am J Obstet Gynecol* [Internet]. 2020 Dec; Available from: <http://dx.doi.org/10.1016/j.ajog.2020.12.1206>

Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibaldi D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, **Bernardini MQ**, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, **May T**, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards DV, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM; OPAL Study Group; AOCs Group, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. *Cancer Epidemiol Biomarkers Prev* [Internet]. 2020 Nov 3; cebp.0739.2020. Available from: <http://dx.doi.org/10.1158/1055-9965.EPI-20-0739>

Gervais NJ, Au A, Almey A, Duchesne A, Gravelins L, Brown A, Reuben R, Baker-Sullivan E, Schwartz DH, Evans K, **Bernardini MQ**, Eisen A, Meschino WS, Foulkes WD, Hampson E, Einstein G. Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause. *Neurobiol Aging* [Internet]. 2020 Oct; 94:1–6. Available from: <http://dx.doi.org/10.1016/j.neurobiolaging.2020.04.019>

Jegatheeswaran K, Cormier B, Dube S, Gotlieb WH, Helpman L, Kwon JS, Lau S, Mah S, **May T**, Saab D, McNeill M, Plante M, Renaud MC, Shamiya S, Vicus D, Parra-Herran C, Feigenberg T. Evaluating the diagnostic performance of preoperative endometrial biopsies in patients diagnosed with high grade endometrial cancer: A study of the Society of Gynecologic Oncology (GOC) Community of Practice (CoP). *Gynecol Oncol* [Internet]. 2020 Oct;159(1):52–7. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.06.510>

Dessources K, Da Cruz Paula A, Pareja F, Stylianou A, **Cybulska P**, Farmanbar A, Chandarlapaty S, Abu-Rustum NR, Reis-Filho JS, Weigelt B, Mueller JJ. Acquisition of APOBEC mutagenesis and microsatellite instability signatures in the development of brain metastases in low-grade, early stage endometrioid endometrial carcinoma. *JCO Precision Oncology* [Internet]. 2020 Oct;(4):1217–23. Available from: <http://dx.doi.org/10.1200/PO.20.00044>

Han K, Mendez L, D'Souza D, Velker V, Barnes E, Milosevic MF, Fyles A, **Ferguson SE**, Taggar A, Croke J, Donovan E, Leung E. Management of gynecologic cancer: Choosing radiotherapy wisely by 3 Southern Ontario academic centers during the COVID-19 pandemic. *Radiother Oncol*[Internet]. 2020 Oct; 151:15–6. Available from: <http://dx.doi.org/10.1016/j.radonc.2020.07.021>

McCuaig J, Care M, **Ferguson SE**, Kim RH, Stockley TL, Metcalfe KA. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. *Gynecol Oncol* [Internet]. 2020 Sep;158(3):747–53. Available from: <http://dx.doi.org/10.1016/j.ygyno.2020.06.507>

Simpson AN, Sutradhar R, **Ferguson SE**, Robertson D, Cheng SY, Baxter NN. Class III obesity and other factors associated with longer wait times for endometrial cancer surgery: A population-based study. *J Obstet Gynaecol Can*[Internet]. 2020 Sep;42(9):1093-1102.e3. Available from: <http://dx.doi.org/10.1016/j.jogc.2020.03.006>

Bell K, Pollett A, Ambus I, Dorman H, Eisen A, **Ferguson SE**, Foster-Gibson C, Graham T, Hughes L, Kim R, Kolvisto I, McCuaig J, O'Neill F, Panabaker K, Sawyer S, Sodhi S, Verbaan D, Wilkins J, Zbuk K. Enhancing clinical cancer genetic service delivery in Ontario – Recommendations for a new model of care. Toronto (Canada): Ontario Health (formerly Cancer Care Ontario); 2020 Nov. Available at: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/67891>

Jacobson M, Coakley N, Bernardini M, Elit L, **Ferguson SE**, Kim R. Risk reduction strategies for BRCA ½ hereditary ovarian cancer syndromes, Toronto (Canada): Ontario Health (formerly Cancer Care Ontario); 2020 Sep. Guideline No.: 4-4v2. Available at: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/931>